The clinical data highlights specific improvements among diverse patient groups. For those who entered the trial with visible ulcers, 36% became ulcer-free by the study's conclusion. Results were notably stronger among advanced therapy-naive participants, where 45% reached endoscopic remission and 49% achieved complete ulcer-free endoscopy.
In section Market Quotes
AbbVie Reports New Clinical Gains for Skyrizi in Crohn’s Treatment
Thirty-six percent of Crohn’s disease patients achieved endoscopic remission during a Phase 3 trial of AbbVie’s Skyrizi, signaling a significant healing of the intestinal lining. The findings, released Tuesday from the Affirm study, provide fresh evidence for the drug's efficacy in addressing chronic inflammation within the gastrointestinal tract.
Crohn’s disease remains a persistent, systemic condition often localized between the small intestine and the colon. AbbVie is currently awaiting regulatory decisions for subcutaneous induction of the drug. Applications for Skyrizi are under review by both the Food and Drug Administration and the European Medicines Agency as the company seeks to expand its footprint in the gastroenterology market.
Comments (0)
No comments yet. Be the first!